Literature DB >> 26198708

'Micro-managers' of hepatic lipid metabolism and NAFLD.

Wei Liu1,2, Hongchao Cao1,2, Jun Yan3, Ruimin Huang4, Hao Ying1,2,5.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is tightly associated with insulin resistance, type 2 diabetes, and obesity. As the defining feature of NAFLD, hepatic steatosis develops as a consequence of metabolic dysregulation of de novo lipogenesis, fatty acid uptake, fatty acid oxidation, and triglycerides (TG) export. MicroRNAs (miRNAs), a class of endogenous small noncoding RNAs, play critical roles in various biological processes through regulating gene expression at post-transcriptional level. A growing body of evidence suggests that miRNAs not only maintain hepatic TG homeostasis under physiological condition, but also participate in the pathogenesis of NAFLD. In this review, we focus on the current knowledge of the hepatic miRNAs associated with the development of liver steatosis and the regulatory mechanisms involved, which might be helpful to further understand the nature of NAFLD and provide a sound scientific basis for the drug development.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26198708     DOI: 10.1002/wrna.1295

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev RNA        ISSN: 1757-7004            Impact factor:   9.957


  12 in total

Review 1.  Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease?

Authors:  Peter Willeit; Philipp Skroblin; Stefan Kiechl; Carlos Fernández-Hernando; Manuel Mayr
Journal:  Eur Heart J       Date:  2016-04-20       Impact factor: 29.983

Review 2.  MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.

Authors:  Zhiqiang Fang; Guorui Dou; Lin Wang
Journal:  Int J Biol Sci       Date:  2021-04-29       Impact factor: 6.580

3.  Mechanistic roles of microRNAs in hepatocarcinogenesis: A study of thioacetamide with multiple doses and time-points of rats.

Authors:  Harsh Dweep; Yuji Morikawa; Binsheng Gong; Jian Yan; Zhichao Liu; Tao Chen; Halil Bisgin; Wen Zou; Huixiao Hong; Tieliu Shi; Ping Gong; Christina Castro; Takeki Uehara; Yuping Wang; Weida Tong
Journal:  Sci Rep       Date:  2017-06-08       Impact factor: 4.379

4.  MiR-30c-5p ameliorates hepatic steatosis in leptin receptor-deficient (db/db) mice via down-regulating FASN.

Authors:  Jiahui Fan; Huaping Li; Xiang Nie; Zhongwei Yin; Yanru Zhao; Chen Chen; Dao Wen Wang
Journal:  Oncotarget       Date:  2017-02-21

5.  miR-26a Potentially Contributes to the Regulation of Fatty Acid and Sterol Metabolism In Vitro Human HepG2 Cell Model of Nonalcoholic Fatty Liver Disease.

Authors:  Omaima Ali; Hebatallah A Darwish; Kamal M Eldeib; Samy A Abdel Azim
Journal:  Oxid Med Cell Longev       Date:  2018-09-30       Impact factor: 6.543

6.  Targeting of miR-96-5p by catalpol ameliorates oxidative stress and hepatic steatosis in LDLr-/- mice via p66shc/cytochrome C cascade.

Authors:  Yukun Zhang; Changyuan Wang; Jiawei Lu; Yue Jin; Canyao Xu; Qiang Meng; Qi Liu; Deshi Dong; Xiaodong Ma; Kexin Liu; Huijun Sun
Journal:  Aging (Albany NY)       Date:  2020-02-05       Impact factor: 5.682

7.  Prevention of Nonalcoholic Hepatic Steatosis by Shenling Baizhu Powder: Involvement of Adiponectin-Induced Inhibition of Hepatic SREBP-1c.

Authors:  Kairui Tang; Yuanjun Deng; Chuiyang Zheng; Huan Nie; Maoxing Pan; Runsen Chen; Jiqian Xie; Qinhe Yang; Yupei Zhang
Journal:  Oxid Med Cell Longev       Date:  2020-06-08       Impact factor: 6.543

Review 8.  Non-Coding RNAs as Potential Novel Biomarkers for Early Diagnosis of Hepatic Insulin Resistance.

Authors:  Ariadna Pielok; Krzysztof Marycz
Journal:  Int J Mol Sci       Date:  2020-06-11       Impact factor: 5.923

9.  miR‑146a improves hepatic lipid and glucose metabolism by targeting MED1.

Authors:  Kun Li; Bao Zhao; Diandian Wei; Wenrui Wang; Yixuan Cui; Lisheng Qian; Guodong Liu
Journal:  Int J Mol Med       Date:  2019-12-27       Impact factor: 4.101

Review 10.  RNA N6-methyladenosine: a promising molecular target in metabolic diseases.

Authors:  Huakui Zhan; Keyang Xu; Yan Li; Jiawen Wang; Chunyan Huang; Meng Shen
Journal:  Cell Biosci       Date:  2020-02-21       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.